TRTheodore Ruel

Theodore Ruel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Theodore Ruel has a total of 231 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Family contributions and challenges to HIV care support among youth in rural Kenya and Uganda during the SEARCH-Youth study

    by Lawrence Owino, Jason Johnson-Peretz, Cecilia Akatukwasa, Anjeline Onyango, Fredrick Atwine, Titus M. O. Arunga, Florence Mwangwa, Marilyn Nyabuti, Moses R. Kamya, Edwin D. Charlebois, et al.

    Adolescents and Young Adults living with HIV (AYAH) rely on caregiver support to achieve optimal HIV treatment outcomes (Mazuze et al., 2021). For this analysis, we consider young people 15–17 year...

  • Harmonization of Data from HIV Implementation Science Trials: Experiences From an NIH Consortium in Africa

    by Sujha Subramanian, Kate O’ROurke, Amanda Fournier, Allison Zerbe, Geri Donenberg, Erin Emerson, Robert Garofalo, Grace John-Stewart, Lisa M. Kuhns, Florence Mwangwa, et al.

  • Open Access

    Youths' strategies for HIV status disclosure in rural Kenya and Uganda: “You can't just trust everyone”

    by Jason Johnson-Peretz, Anjeline Onyango, Cecilia Akatukwasa, Fredrick Atwine, Lawrence Owino, Titus M.O. Arunga, Marilyn Nyabuti, Janice Litunya, Jane Kabami, Florence Mwangwa, et al.


  • HIV Resistance to Dolutegravir Varies With Coadministered Agents

    by Ingrid A Beck, Ceejay L Boyce, Marley D Bishop, Alyssa R Oldroyd, Louise du Toit, Amashnee Saimen, Kholofelo Mn Ramarope, Sonia Hitchcock, Nicolette M du Plessis, Loice Mbogo, et al.

    We hypothesized that HIV-dolutegravir resistance is more frequent when coadministered with nucleos(t)ides with shorter intracellular half-lives. Multivariable analysis of 183 viremic (≥200 c/mL) participants from 4 cohorts (N = 660 participants) found dolutegravir resistance in 21 (11.5%). Dolutegravir resistance was greater with dolutegravir + lamivudine + zidovudine/(1 on stavudine) (odds ratio [OR] = 19.4, 95% confidence interval [CI]: 5.1–74.3) or dolutegravir + lamivudine +abacavir (OR = 5.4, 95% CI: 1.1–25.8), compared with dolutegravir + lamivudine + tenofovir.


  • Open Access

    The Effect of a Life-Stage Based Intervention on Depression in Youth Living with HIV in Kenya and Uganda: Results from the SEARCH-Youth Trial

    by Florence Mwangwa, Jason Johnson-Peretz, James Peng, Laura B. Balzer, Janice Litunya, Janet Nakigudde, Douglas Black, Lawrence Owino, Cecilia Akatukwasa, Anjeline Onyango, et al.

    Depression among adolescents and young adults with HIV affects both their wellbeing and clinical care outcomes. Integrated care models are needed. We hypothesized that the SEARCH-Youth intervention, a life-stage-based care model that improved viral suppression, would reduce depressive symptoms as compared to the standard of care. We conducted a mixed-methods study of youth with HIV aged 15–24 years in SEARCH-Youth, a cluster-randomized trial in rural Uganda and Kenya (NCT03848728). Depression was assessed cross-sectionally with the PHQ-9 screening tool and compared by arm using targeted minimum loss-based estimation. In-depth semi-structured interviews with young participants, family members, and providers were analyzed using a modified framework of select codes pertaining to depression. We surveyed 1,234 participants (median age 21 years, 80% female). Having any depressive symptoms was less common in the intervention arm (53%) compared to the control (73%), representing a 28% risk reduction (risk ratio: 0.72; CI: 0.59–0.89). Predictors of at least mild depression included pressure to have sex, physical threats, and recent major life events. Longitudinal qualitative research among 113 participants found that supportive counseling from providers helped patients build confidence and coping skills. Integrated models of care that address social threats, adverse life events, and social support can be used to reduce depression among adolescents and young adults with HIV.


  • Open Access

    Midwives as trainers for a neonatal clinical decision support system at four rural health facilities in eastern Uganda: a mixed-methods observational study

    by Mary Kakuru Muhindo, Jean Armas, Moses Kamya, Elon Danziger, Joshua Bress, Theodore Ruel

    Objectives To evaluate acceptability and effectiveness of midwives as trainers for NoviGuide, a neonatal clinical decision support system (CDSS). Design A 20-months, mixed-methods open cohort study. Settings and participants Nurse-midwives at four rural health facilities in eastern Uganda. Methods We developed a midwife-led trainer programme and instructed two midwives as NoviGuide Trainers in three 3-hour-long sessions. Trainers trained all nurse-midwives at each site in single 3-hour-long sessions. Using the Kirkpatrick model, we evaluated acceptability at level 1 for participant’s reaction and level 3 for participant’s attitudes towards the programme. We evaluated effectiveness at level 2 for newly learnt skills, and level 3 for participant’s uptake of NoviGuide and perception of newborn care practices. We used surveys and focus groups at baseline, 3 months and 6 months and viewed usage data from September 2020 through May 2022. Results All 49 participants were female, 23 (46.9%) owned smartphones, 12 (24.5%) accessed the internet daily and 17 (34.7%) were present by study end following staff changes. All participants perceived the use of midwives as NoviGuide Trainers to be an acceptable approach to introduce NoviGuide (mean 5.9 out of 6, SD 0.37). Participants reported gaining new skills and confidence to use NoviGuide; some, in turn, trained others. Participants reported improvement in newborn care. Uptake of NoviGuide was high. Of 49 trained participants, 48 (98%) used NoviGuide. A total of 4045 assessments of newborns were made. Of these, 13.8% (558/4045) were preterm, 17.5% (709/4045) weighed under 2.5 kg and 21.1% (855/4045) had a temperature Conclusion This midwife-led programme was acceptable and led to self-reported improvement in newborn care and high uptake of NoviGuide among nurse-midwives. Task shifting CDSS expert roles to midwives could facilitate large-scale implementation. However, resources like internet coverage, reliable electricity and mobile devices should be considered in low-resource settings.


  • Open Access

    Novel Approaches to Postnatal Prophylaxis to Eliminate Vertical Transmission of HIV

    by Theodore Ruel, Martina Penazzato, Jennifer M. Zech, Moherndran Archary, Tim R. Cressey, Ameena Goga, Joseph Harwell, Raphael J. Landovitz, Maria Grazia Lain, Marc Lallemant, et al.

    Key Messages Postnatal prophylaxis continues to play an essential role in efforts to eliminate new pediatric HIV infections and maximize HIV-free survival. New approaches to postnatal prophylaxis using currently available modern oral antiretroviral drugs could surmount many current barriers. Long-acting agents and delivery platforms currently in development for treating people living with HIV have great potential as postnatal prophylaxis for infants. Studies of novel postnatal prophylactic agents are possible and imperative in the near future and must be prioritized early in the antiretroviral drug development pipeline. Close collaboration between researchers, community representatives, industry, regulators, and policymakers will be the critical ingredient to ensure HIV-free survival for all infants with HIV exposure.


  • Open Access

    Two or more significant life-events in 6-months are associated with lower rates of HIV treatment and virologic suppression among youth with HIV in Uganda and Kenya

    by Florence Mwangwa, Edwin D. Charlebois, James Ayieko, Winter Olio, Douglas Black, James Peng, Dalsone Kwarisiima, Jane Kabami, Laura B. Balzer, Maya L. Petersen, et al.

    Youth living with HIV in sub-Saharan Africa have poor HIV care outcomes. We determined the association of recent significant life-events with HIV antiretroviral treatment (ART) initiation and HIV viral suppression in youth aged 15–24 years living with HIV in rural Kenya and Uganda. This was a cross-sectional analysis of 995 youth enrolled in the SEARCH Youth study. At baseline, providers assessed recent (within 6 months) life-events, defined as changes in schooling/employment, residence, partnerships, sickness, incarceration status, family strife or death, and birth/pregnancy, self-reported alcohol use, being a parent, and HIV-status disclosure. We examined the frequencies of events and their association with ART status and HIV viral suppression (2 significant life-events (aOR = 0.61, 95% CI:0.45-0.85) and consuming alcohol (aOR = 0.61, 95% CI:0.43-0.87) were associated with a lower odds of HIV viral suppression, while disclosure of HIV-status to partner (aOR = 2.39, 95% CI:1.6-3.5) or to family (aOR = 1.86, 95% CI:1.3-2.7), being a parent (aOR = 1.8, 95% CI:1.2-2.5), and being single (aOR = 1.6, 95% CI:1.3-2.1) had a higher odds. This suggest that two or more recent life-events and alcohol use are key barriers to ART initiation and achievement of viral suppression among youth living with HIV in rural East Africa. Trial registration: ClinicalTrials.gov identifier: NCT03848728..


  • Open Access

    Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial

    by Theodore D Ruel, Edward P Acosta, Jessica P Liu, Kathryn P Gray, Kathleen George, Nicole Montañez, Stephanie Popson, Ann M Buchanan, Mattie Bartlett, Dale Dayton, et al.


  • Open Access

    A Mobile Health App (WYZ) for Engagement in Care and Antiretroviral Therapy Adherence Among Youth and Young Adults Living With HIV: Single-Arm Pilot Intervention Study

    by Parya Saberi, Nadra E Lisha, Xavier A Erguera, Estie Sid Hudes, Mallory O Johnson, Theodore Ruel, Torsten B Neilands

    Background: Youth are globally recognized as being vulnerable to HIV. Younger age has been correlated with worse health outcomes. Mobile health (mHealth) interventions have the potential to interact with youth where they are, using a device they already access. Objective: Using predefined benchmarks, we sought to evaluate the feasibility and acceptability of WYZ, an mHealth app, for improved engagement in care and antiretroviral therapy (ART) adherence among youth and young adults living with HIV. WYZ was designed and developed with input from youth and young adults living with HIV using a human-centered design approach and was based on the information, motivation, and behavioral skills framework to address common barriers to care and ART adherence among youth and young adults living with HIV. Methods: We recruited youth and young adults living with HIV (18-29 years old) from the San Francisco Bay Area to take part in a 6-month pilot trial. Their participation included completing baseline and exit surveys, and participating in seven phone check-ins about their use of WYZ. Results: Youth and young adults living with HIV (N=79) reported high levels of feasibility and acceptability with WYZ use. We met predefined benchmarks for recruitment (79/84, 94%), mean logins per week (5.3), tracking ART adherence (5442/9393, 57.9%), posting chat topics per week (4.8), and app crashes reported per week (0.24). The ease of app download, install, and setup, and comfort with security, privacy, and anonymity were highly rated (all over 91%). Additionally, participants reported high satisfaction for a research project that was remotely conducted. Participants used the app for shorter timeframes compared to the predefined benchmark. Conclusions: We noted high feasibility and acceptability with WYZ. Further research to examine the efficacy of WYZ will enable youth and young adults living with HIV and their providers to make informed decisions when using, recommending, and prescribing the app for improved engagement in HIV care and ART adherence. Trial Registration: ClinicalTrials.gov NCT03587857; https://clinicaltrials.gov/ct2/show/NCT03587857